From: Global health trials methodological research agenda: results from a priority setting exercise
Round 1 N = 412 | Round 2 N = 314 | |
---|---|---|
Years of experience working in clinical trials | ||
Mean (SD) | 7.67 (7.02) | 7.89 (7.14) |
Median (IQR) | 5 (3, 10) | 6 (3, 10) |
Range | 1, 45 | 1, 50 |
Participant disciplines | ||
Clinical disciplines | 268 (65%) | 196 (62%) |
Public health | 59 (14%) | 47 (15%) |
Infectious diseases | 57 (14%) | 40 (13%) |
General medicine | 48 (12%) | 27 (9%) |
Paediatrics | 24 (6%) | 14 (4%) |
General surgery | 17 (4%) | 13 (4%) |
Nursing | 9 (2%) | 7 (2%) |
Obstetrics | 8 (2%) | 12 (4%) |
Primary care | 8 (2%) | 7 (2%) |
Psychiatry | 8 (2%) | 3 (1%) |
Dentistry | 5 (1%) | 2 (1%) |
Oncology | 5 (1%) | 4 (1%) |
Physiotherapy | 3 (1%) | 3 (1%) |
Cardiology | 2 (<1%) | 1 (< 1%) |
Gynaecology | 2 (< 1%) | 1 (< 1%) |
Haematology | 2 (< 1%) | 2 (1%) |
Neurosurgery | 2 (< 1%) | 1 (< 1%) |
Anaesthesia | 1 (< 1%) | 1 (< 1%) |
Dermatology | 1 (< 1%) | 1 (< 1%) |
Ear, nose and throat diseases | 1 (< 1%) | 1 (< 1%) |
Neurology | 1 (< 1%) | 0 (0%) |
Nutrition | 1 (< 1%) | 2 (1%) |
Orthopaedics and trauma | 1 (< 1%) | 6 (2%) |
Pneumology | 1 (< 1%) | 0 (0%) |
Rheumatology | 1 (< 1%) | 1 (< 1%) |
Urology | 1 (< 1%) | 0 (0%) |
Research methods disciplines | 85 (21%) | 61 (19%) |
Trials management | 37 (9%) | 19 (6%) |
Statistics | 19 (5%) | 16 (5%) |
Data management | 13 (3%) | 10 (3%) |
Epidemiology | 7 (2%) | 8 (3%) |
Ethics | 3 (1%) | 2 (1%) |
Quality assurance | 2 (< 1%) | 2 (1%) |
Clinical research | 2 (< 1%) | 2 (1%) |
Health economics | 1 (< 1%) | 1 (< 1%) |
Information systems | 1 (< 1%) | 0 (0%) |
Mathematics | 0 (0%) | 1 (< 1%) |
Laboratory science disciplines | 37 (9%) | 44 (14%) |
Biomedical sciences | 12 (3%) | 27 (9%) |
Pharmacy | 12 (3%) | 10 (3%) |
Parasitology | 4 (1%) | 5 (2%) |
Immunology | 3 (1%) | 0 (0%) |
Biology | 2 (< 1%) | 0 (0%) |
Microbiology | 2 (< 1%) | 1 (< 1%) |
Biotechnology | 1 (< 1%) | 1 (< 1%) |
Chemistry | 1 (< 1%) | 0 (0%) |
Other disciplines | 22 (5%) | 13 (4%) |
Health management (administration) | 6 (1%) | 3 (1%) |
Social sciences | 6 (1%) | 4 (1%) |
Community engagement | 3 (1%) | 1 (< 1%) |
Complementary medicine | 3 (1%) | 2 (1%) |
Pharmacology | 2 (< 1%) | 1 (< 1%) |
Medical devices | 1 (< 1%) | 0 (0%) |
Pharmacogenomics | 1 (< 1%) | 0 (0%) |
Global health | 0 (0%) | 1 (< 1%) |
Environmental heath | 0 (0%) | 1 (< 1%) |
Origin of trial experience | ||
In a low- to middle-income country (LMIC) only | 250 (61%) | 196 (63%) |
In both a LMIC and a high-income country (HIC) | 100 (24%) | 76 (24%) |
In a HIC only | 62 (15%) | 42 (13%) |
Involvement in clinical trials | ||
Design | 240 (58%) | 174 (55%) |
Conduct | 361 (88%) | 267 (85%) |
Analysis | 213 (53%) | 171 (54%) |
Reporting | 257 (62%) | 200 (64%) |
Current residence by continent | ||
Africa | 210 (51%) | 171 (54%) |
Asia | 82 (20%) | 55 (18%) |
Europe | 64 (16%) | 41 (13%) |
South America | 32 (8%) | 30 (10%) |
North America | 23 (6%) | 16 (5%) |
Australia | 1 (< 1%) | 1 (< 1%) |